Zacks Investment Research downgraded Auris Medical Holding AG (NASDAQ:EARS) to Sell in a report released today.
- Updated: September 19, 2016
Only yesterday Auris Medical Holding AG (NASDAQ:EARS) traded 0.00% even at $1.67. EARS’s 50-day average is $2.76 and its two hundred day average is $3.56. With the last stock close down 53.07% from the 200-day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same time. 181,473 shares of the stock exchanged hands, down from ann average trading volume of 590,748.
Zacks Investment Research has downgraded Auris Medical Holding AG(NASDAQ:EARS) to Sell in a report released 9/19/2016.
Also covering Auris Medical Holding AG’s stock price target, a total of 4 brokers have issued a report on the stock. The one year target is $11.75 with two analysts rating the company a strong buy, two analysts rating the stock a buy, 0 firms rating the stock a hold, 0 rating the stock to underperform, and finally 0 analysts rating the stock as sell.
Auris Medical Holding AG has a one-year low of $1.55 and a one-year high of $7.96 and has a market cap of $0.0.
General Information About Auris Medical Holding AG (NASDAQ:EARS)
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.